Abstract:Purpose/Objective(s)Plasma HPV DNA could detect molecular residual disease (MRD) after (chemo)radiotherapy (CRT/RT) for oropharyngeal cancer (OPC). Whole HPV genome sequencing (HPV-seq) could both genotype and quantify HPV DNA more sensitively than digital polymerase chain reaction (dPCR). We compared HPV-seq and dPCR pre- and post-RT in a large, prospective OPC cohort. We hypothesized that HPV-seq is more sensitive and more accurately predicts recurrence by MRD.Materials/MethodsWe recruited patients (pts) with non-metastatic p16-positive OPC (TNM8 stage I-III) undergoing curative-intent CRT/RT. Each pt had peripheral blood plasma prospectively collected at pre-RT and 3-months post-RT. The primary endpoint was recurrence-free survival (RFS) and secondary endpoint was overall survival (OS). Time-to-event analysis was performed using the Kaplan-Meier method with log-rank tests and multivariable Cox regression. HPV-seq was performed using a validated hybrid capture panel targeting 38 HPV genomes and 15 recurrently mutated genes in OPC. dPCR was performed using a validated multiplexed assay targeting HPV16 E6/E7. HPV DNA levels were expressed as copies/mL plasma and log-transformed for statistical tests.ResultsWe performed HPV-seq and dPCR on pre- and post-RT samples from 245 pts. Median follow-up was 52.3 (4.5-95.8) months, and 3-yr RFS was 87.9%. HPV-seq detected plasma HPV DNA in 237 (97%) pts pre-RT (HPV16-only: 161, non-HPV16: 16, mixed: 60) with 0.017-364867 copies/mL. Of pre-RT samples with HPV-16 reads detected on HPV-seq, HPV-16 dPCR was detectable in 202/221 (91%), with 0.32-37313 copies/mL on dPCR. Copies of HPV16 DNA per mL were strongly correlated between HPV-seq and dPCR (R=0.986). Post-RT, HPV-seq detected residual HPV DNA in 48 (20%) pts. Of these, dPCR detected 19 and did not detect 29, of which 6 had non-HPV16, and the other 23 had HPV16 with <1.37 copies/mL. Of pts with 3-year recurrence, post-RT detection of HPV DNA by HPV-seq predicted 16/23 (sensitivity=70%, NPV=95.5%, AUC=0.81) and by dPCR predicted 7/23 (sensitivity=30%, NPV=91.0%, AUC=0.63). Post-RT residual HPV DNA on HPV-seq was associated with poorer RFS (3-yr 58% vs. 96%, p<0.0001) and OS (3-yr 61.4% vs. 97.1%, p<0.0001). Of 192 pts with HPV16 undetectable by dPCR at post-RT, the 23 with residual HPV DNA detected by HPV-seq still had poorer RFS (3-yr 62.5% vs. 95.7%, p<0.0001) and OS (3-yr 75.0% vs. 96.9%, p<0.0001) than those with HPV-seq clearance. Adjusting for T and N staging, post-RT residual HPV16 DNA was independently prognostic of RFS and OS by either assay, with odds ratios for RFS of 14.91 [6.19, 35.94] for HPV-seq and 5.17 [2.09, 12.81] for dPCR.ConclusionWhole viral genome sequencing genotypes and quantifies plasma HPV DNA. Pts with residual HPV DNA had poorer RFS and OS, independent of stage. For HPV16, HPV-seq and dPCR are strongly correlated, but HPV-seq is more sensitive with higher negative predictive value and predicted 2.3x more 3-year recurrences in OPC pts.

Circulating tumor HPV DNA in the management of HPV+ oropharyngeal cancer and its correlation with MRI

Circulating HPV Tumor DNA and Molecular Residual Disease in HPV-Positive Oropharyngeal Cancers: A Scoping Review

12P Exploring the Prognostic Value of Circulating Tumor HPV DNA in Cervical Cancer

Pre-Treatment Circulating Tumor Human Papillomavirus (HPV) DNA and Recurrence Risk in HPV Associated Malignancy: Oropharyngeal, Anal Canal, and Cervical Cancer

Preliminary Results from Retrospective Correlation of Circulating Tumor DNA (ct-DNA) with Imaging for HPV-positive Oropharyngeal Squamous Cell Carcinoma

Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer

HPV Serology and Circulating Viral DNA for Detection, Genotyping, and Risk-Stratification in P16+ Oropharyngeal Cancer

Ultrasensitive Liquid Biopsy in Patients with P16-Positive Oropharyngeal Cancer Using HPV-seq

Abstract 2297: Longitudinal monitoring of HPV circulating tumor DNA in cervical cancer

Assessing the feasibility of a multimodal liquid biopsy for the diagnosis of HPV-associated oropharyngeal squamous cell carcinoma

ctDNA predicts recurrence and survival in stage I and II HPV-associated head and neck cancer patients treated with surgery

Prospective validation of ctHPVDNA for detection of minimal residual disease and prediction of recurrence in patients with HPV-associated head and neck cancer treated with surgery.

Abstract 2412: Circulating HPV DNA as a potential biomarker to monitor response to the pembrolizumab and vorinostat combination in patients with squamous cell carcinoma of different locations

Pretreatment Circulating HPV16 DNA Viral Load Predicts Risk of Distant Metastasis in Patients with HPV16-Positive Oropharyngeal Cancer

Determinants of the level of circulating-tumor HPV16 DNA in patients with HPV-associated oropharyngeal cancer at the time of diagnosis

Multi-feature next-generation liquid biopsy for diagnosis and prognosis in HPV-associated head and neck cancer.

Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease after Chemoradiation in Cervical Cancer

Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer

Development of a high-performance multi-probe droplet digital PCR assay for high-sensitivity detection of human papillomavirus circulating tumor DNA from plasma

Prognostic value of HPV circulating tumor DNA detection and quantification in locally advanced cervical cancer

Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Cervical Cancer Patients Undergoing Definitive Chemoradiation